The treatment of Gram-negative infections is increasingly compromised by the 28 spread of resistance. With few agents currently in development clinicians are now 29 considering the use of un-orthodox combination therapies for multi-drug resistant 30 strains. Here we assessed the in-vitro activity of the novel lipoglycopeptide 31 telavancin (TLV) when combined with colistin (COL) versus 13 Gram-negative type 32 strains and 66 clinical isolates. Marked synergy was observed in either checkerboard 33 (FICI < 0.5, SBPI > 2) or time-kill assays (>2 log reduction in viable counts compared 34 with starting inocula at 24 hours) versus the majority of COL susceptible 35
INTRODUCTION 44 45
Multi-drug resistant (MDR) bacteria represent an enormous challenge to modern 46 healthcare systems. Although some new agents have been introduced in the last 10 47
MATERIALS AND METHODS 84 85

Antimicrobial Compounds 86
Colistin Sulfate (COL) was obtained from Sigma Aldrich Ltd (Poole, Dorset, UK) and 87 telavancin (TLV) from Astellas Pharma Europe (Lot no. 07-2460). Stock solutions of 88 10,000 µg/ml (COL) and 2,000 µg/ml (TLV) were prepared in sterile distilled water or 89 100% dimethylsulfoxide (DMSO), respectively and diluted with IsoSensitest broth 90 (Oxoid, Basingstoke, UK) to working strength concentrations. 91
92
Bacterial Strains 93
Representative bacterial type strains were obtained from the National Collection of 94 Synergy between telavancin and colistin was assessed in microtitre plate 110 checkerboard assays. Plates were set up with increasing concentrations of 111 telavancin (0 -128 µg/ml) in each column and colistin (0 -8 µg/ml) in each row. 112
Wells were inoculated with 10 5 cfu/ml of the test organism and incubated at 37ºC for 113 18 hrs in 5% CO 2 . Checkerboards containing S. maltophilia as the test organism 114 were incubated at 30ºC (10). Plates were assessed for turbidity by eye and absence 115 of growth in non-turbid wells was confirmed by the addition of 5 µl of alamarBlue® 116 reagent (Invitrogen, Paisley, UK); a redox dye which turns red in the presence of 117 metabolically active bacteria. 6 CFU / ml prepared from an overnight culture was used and serial 139 dilutions were plated onto IsoSensitest agar plates at 0, 2, 4, 6 and 24 hr time points. 140
Bactericidal activity was defined as a >3 log reduction in the viable count at each 141 time point and synergy as a >2 log reduction in viable count at 24 hrs compared to 142 the starting inoculum. 143
144
Synergy screen versus clinical isolates 145
A screen for TLV / COL synergy was also conducted using the 13 type strains and 146 66 random COL-susceptible Gram-negative clinical isolates. These consisted of 43 147 non-fermenters (A. baumannii n=35, S. maltophilia n=8) and 23 Enterobacteriaceae 148 The 11 bacterial type strains were all highly resistant to TLV, with a MIC of > 32 164 µg/ml when determined by Etest and > 128 µg/ml in broth microtitre dilution plates. 165
The P. mirabilis NCTC 13376 and S. marcescens NCTC 13382 isolates were both 166 highly resistant to COL (> 256 µg/ml), a property intrinsic to these species, as was 167 one of the E. cloacae type strains (NCTC 10005). The remaining eight organisms 168
were considered susceptible to COL (MIC < 2 µg/ml by Etest) ( Table 1) . COL MICs 169
were typically 4-5 fold higher when determined by broth microtitre dilution and up to 170 256 fold higher in the kinetic assays (Table 1) . 171
172
In checkerboard assays, synergy (FICI ≤ 0.5) was observed when TLV was 173 combined with COL against all of the COL susceptible isolates with the exception of 174 E. cloacae NCTC 13380 and P. aeruginosa NCTC 27853. The combination had no 175 significant effects on any of the COL resistant strains. Calculation of the susceptible 176 breakpoint index for strains with a TLV / COL FICI ≤ 0.5 revealed an SBPI of > 2 for 177 each (range 3-10) suggesting that the strength of the interaction observed was 178 consistent with currently accepted TLV and COL pharmacodynamic breakpoints 179 (Table 1) . 180 181
Time-kill assays 182
Killing of each of the type strains by TLV (20 µg/ml), COL (0.5 x MIC) and TLV in 183 combination with COL was assessed over 24 hours using time-kill methodology. TLV 184 had no effect alone and viable counts were comparable to untreated controls. isolates, this was not sustained and each isolate was able to re-grow to a bacterial 187 density higher than the starting inoculum, apart from K. pneumoniae NCTC 13368 188 (Figure 2) . However, the addition of TLV (20 µg/ml) resulted in continued bactericidal 189 activity and synergy (> 2 log reduction in CFU/ml) after 24 hours versus five of the 190 type strains tested (Table 1) . The erosion of effective treatments by resistance, combined with a drug 205 development pipeline that is almost dry, has renewed the interest in using un-206 orthodox therapies for Gram-negative infections. In this study we looked at the 207 effects of combining the polymyxin E derivative COL with the novel lipoglycopeptide, 208
TLV. Using a number of methods we demonstrated that in-vitro, TLV was highly 209 active when combined with COL against A. baumannii, E. coli, K. pneumoniae, 210
Enterobacter spp and S. maltophilia type strains and representative clinical isolates. 211
When used together, the drugs were not only synergistic, but also bactericidal, 212
prevented the re-growth of COL exposed bacteria in time-kill assays, with the 213 exception of S. maltophilia NCTC 10258. These data suggest that a TLV / COL 214 combination could be a useful option for the treatment of complicated Gram-negative 215 bacterial infections. 216
217
We were unable to demonstrate significant synergy versus any of the isolates 218 exhibiting COL resistance, most likely due to the inability of COL to disrupt the outer 219 membrane of these strains. In P. mirabilis and S. marcescens, resistance to COL is 220 an intrinsic property mediated by modifications to phosphate residues within the 221 (24), (28) and it may 229 prove useful to investigate the activity of glycopeptides in combination with these 230
compounds. 231 232
The combination was also only found to be synergistic versus P. aeruginosa NCTC 233 27853, in the time-kill assay despite the strain appearing to be fully susceptible to 234 COL using static methods (Etest, broth microtitre dilution). When polymyxins have 235 been combined with other antimicrobials usually inactive against P. aeruginosa 236 (macrolides, rifampicin), marked synergy has been reported, suggesting that COL is 237 at least capable of permeabilizing the membrane of this organism (22). Interestingly, 238 the NCTC 27853 strain has recently been shown to exhibit a heteroresistant 239 phenotype when subjected to population analysis (2). This could explain our 240 observations in the time-kill assay whereby COL exposure leads to the selection of a 241 resistant subpopulation, susceptible to the action of TLV. Heteroresistance to COL is 242 increasingly reported in both type strains and clinical isolates. Although we did not 243 undertake a formal population analysis this appears to be a property of the E. coli 244 NCTC 12241 isolate as COL resistance was readily selected at 0.5 x MIC even when 245 combined with TLV (Figure 2) . 246 247 TLV is the latest glycopeptide to be studied in combination with COL. Its 248 antimicrobial activity can clearly be potentiated by COL not just towards MDRAB but 249 also a wider range of Gram-negative species. Although these in-vitro studies did not 250 evaluate other glycopeptides, the selection of TLV may provide some practical could be assessed to determine the optimum combination to maximize activity 286 against Gram-negatives whilst minimizing potential adverse events. 287
288
Although we were able to show synergy against a range of COL-susceptible bacteria 289 this was still species and strain specific. In view of this we would not advocate use of 290 COL / glycopeptide combinations without prior in-vitro evidence of potential benefit. 291
This may prove to be a problem, as current methods for assessing the strength of 292 antimicrobial combinations are not practical for most routine diagnostic laboratories. 293
Synergy testing using time-kill methodology is extremely labour intensive, as are 294 checkerboard assays if custom made pre-diluted plates are not available. Automated 295 platforms are also usually not configured to assess the activity of drugs in 296 combination. Laboratories are likely to be asked to investigate the potential of an un-297 orthodox combination on a case by case basis, either due to multi-drug resistance or 298 complications with conventional therapies. We suggest that an Etest-based method, 299 such as the one used here may be the most adaptable methodology to employ in 300 this setting. 
